Browse > Article
http://dx.doi.org/10.5223/pghn.2020.23.1.35

Risk and Protective Factors for Gastrointestinal Symptoms associated with Antibiotic Treatment in Children: A Population Study  

Bau, Mario (Department of Pediatric, Ospedale "F. Del Ponte", University of Insubria)
Moretti, Alex (Department of Pediatric, Ospedale "F. Del Ponte", University of Insubria)
Bertoni, Elisabetta (Department of Pediatric, Ospedale "F. Del Ponte", University of Insubria)
Vazzoler, Valentino (Department of Statistic, University of Padua)
Luini, Chiara (Department of Pediatric, Ospedale "F. Del Ponte", University of Insubria)
Agosti, Massimo (Department of Pediatric, Ospedale "F. Del Ponte", University of Insubria)
Salvatore, Silvia (Department of Pediatric, Ospedale "F. Del Ponte", University of Insubria)
Publication Information
Pediatric Gastroenterology, Hepatology & Nutrition / v.23, no.1, 2020 , pp. 35-48 More about this Journal
Abstract
Purpose: Gastrointestinal symptoms are often related to antibiotic treatment. Their incidence, risk and protective conditions in children are not well defined and represent the aims of this study. Methods: We prospectively enrolled inpatient children submitted to antibiotic treatment. Indication, type, dose and duration of treatment, probiotic supplementation and gastrointestinal symptoms were recorded at recruitment, after two and four weeks. Antibiotic-associated diarrhea (AAD) was defined as the presence of at least 3 loose/liquid stools within 14 days from antibiotic onset. Results: AAD occurred in 59/289 (20.4%) of patients, with increased risk in children younger than 3 years (relative risk [RR]=4.25), in lower respiratory (RR=2.11) and urinary infections (RR=3.67), intravenous administration (RR=1.81) and previous AAD episodes (RR=1.87). Abdominal pain occurred in 27/289 (9.3%), particularly in children >6 years (RR=4.15), with previous abdominal pain (RR=7.2) or constipation (RR=4.06). Constipation was recorded in 23/289 (8.0%), with increased risk in children having surgery (RR=2.56) or previous constipation (RR=7.38). Probiotic supplementation significantly reduced AAD (RR=0.30) and abdominal pain (RR=0.36). Lactobacillus rhamnosus GG (LGG) and L. reuteri significantly reduced AAD (RR=0.37 and 0.35) and abdominal pain (RR=0.37 and 0.24). Conclusion: AAD occurred in 20.4% of children, with increased risk at younger age, lower respiratory and urinary tract infections, intravenous treatment and previous AAD. LGG and L. reuteri reduced both AAD and associated abdominal pain.
Keywords
Abdominal pain; Anti-bacterial agents; Antibiotic-associated diarrhea; Children; Constipation; Diarrhea; Lactobacillus reuteri; Lactobacillus rhamnosus GG; Probiotics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Patro-Golab B, Shamir R, Szajewska H. Yogurt for treating antibiotic-associated diarrhea: systematic review and meta-analysis. Nutrition 2015;31:796-800.   DOI
2 Akobeng AK. Communicating the benefits and harms of treatments. Arch Dis Child 2008;93:710-3.   DOI
3 Guo B, Yuan Y. A comparative review of methods for comparing means using partially paired data. Stat Methods Med Res 2017;26:1323-40.   DOI
4 Johnston BC, Shamseer L, da Costa BR, Tsuyuki RT, Vohra S. Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. Pediatrics 2010;126:e222-31.   DOI
5 Castelluzzo MA, Tarsitano F, Pensabene F. Approccio al bambino con disturbi funzionali gastrointestinali. Prosp in Ped 2016;46:276-89.
6 Robinson CJ, Young VB. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 2010;1:279-84.   DOI
7 Haran JP, Hayward G, Skinner S, Merritt C, Hoaglin DC, Hibberd PL, et al. Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics. Am J Emerg Med 2014;32:1195-9.   DOI
8 Szajewska H. What are the indications for using probiotics in children? Arch Dis Child 2016;101:398-403.   DOI
9 Urbanska M, Gieruszczak-Bialek D, Szajewska H. Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children. Aliment Pharmacol Ther 2016;43:1025-34.   DOI
10 Uusijarvi A, Bergstrom A, Simren M, Ludvigsson JF, Kull I, Wickman M, et al. Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain--a Swedish birth cohort study. Neurogastroenterol Motil 2014;26:841-50.   DOI
11 Pensabene L, Talarico V, Concolino D, Ciliberto D, Campanozzi A, Gentile T, et al.; Post-Infectious Functional Gastrointestinal Disorders Study Group of Italian Society for Pediatric Gastroenterology, Hepatology and Nutrition. Postinfectious functional gastrointestinal disorders in children: a multicenter prospective study. J Pediatr 2015;166:903-7.e1.   DOI
12 Saps M, Pensabene L, Di Martino L, Staiano A, Wechsler J, Zheng X, et al. Post-infectious functional gastrointestinal disorders in children. J Pediatr 2008;152:812-6.e1.   DOI
13 Saps M, Pensabene L, Turco R, Staiano A, Cupuro D, Di Lorenzo C. Rotavirus gastroenteritis: precursor of functional gastrointestinal disorders? J Pediatr Gastroenterol Nutr 2009;49:580-3.   DOI
14 Salvatore S, Pensabene L, Borrelli O, Saps M, Thapar N, Concolino D, et al. Mind the gut: probiotics in paediatric neurogastroenterology. Benef Microbes 2018;9:883-98.   DOI
15 Smith JT, Smith MS. Does a preoperative bowel preparation reduce bowel morbidity and length of stay after scoliosis surgery? A randomized prospective study. J Pediatr Orthop 2013;33:e69-71.   DOI
16 Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2015;(12):CD004827.
17 Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr 2014;103:365-72.   DOI
18 Hojsak I. Probiotics in functional gastrointestinal disorders. Adv Exp Med Biol 2019;1125:121-37.   DOI
19 Newlove-Delgado T, Abbott RA, Martin AE. Probiotics for children with recurrent abdominal pain. JAMA Pediatr 2019;173:183-4.   DOI
20 Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics 2012;130:23-31.   DOI
21 Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2012;35:1355-69.   DOI
22 Reed DE, Vanner SJ. Emerging studies of human visceral nociceptors. Am J Physiol Gastrointest Liver Physiol 2017;312:G201-7.   DOI
23 Cai J, Zhao C, Du Y, Zhang Y, Zhao M, Zhao Q. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: systematic review with network meta-analysis. United European Gastroenterol J 2018;6:169-80.   DOI
24 Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, et al.; ESPGHAN Working Group for ProbioticsPrebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr 2016;62:495-506.   DOI
25 World Health Organization. Diarrhoeal Disease Fact Sheet [Internet]. Geneva: World Health Organization; 2017 [cited 2019 Aug date]. Available from: https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease
26 McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol 2016;22:3078-104.   DOI
27 Reyes H, Guiscafre H, Munoz O, Perez-Cuevas R, Martinez H, Gutierrez G. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997;50:1297-304.   DOI
28 Turck D, Bernet JP, Marx J, Kempf H, Giard P, Walbaum O, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003;37:22-6.   DOI
29 McFarland LV. [Risk factor for antibiotic-associated diarrhea. A review of the literature]. Ann Med Interne (Paris) 1998;149:261-6 French.
30 McFarland LV, Goh S. Preventing pediatric antibiotic-associated diarrhea and Clostridium difficile infections with probiotics: a meta-analysis. World J Meta-Anal 2013;1:102-20.   DOI
31 Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004;50:234-6.   DOI
32 Murphy JL, Fenn N, Pyle L, Heizer H, Hughes S, Nomura Y, et al. Adverse events in pediatric patients receiving long-term oral and intravenous antibiotics. Hosp Pediatr 2016;6:330-8.   DOI
33 Li N, Zheng B, Cai HF, Chen YH, Qiu MQ, Liu MB. Cost-effectiveness analysis of oral probiotics for the prevention of Clostridium difficile-associated diarrhoea in children and adolescents. J Hosp Infect 2018;99:469-74.   DOI
34 Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. Gastroenterology 2016. doi: 10.1053/j.gastro.2016.02.015. [Epub ahead of print].
35 Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 2016. doi: 10.1053/j.gastro.2016.02.016. [Epub ahead of print].
36 Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, et al.; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; North American Society for Pediatric Gastroenterology. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014;58:258-74.   DOI